AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.

A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030.

AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free survival endpoint,

AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.

The uptick in AstraZeneca share price came after the company announced that it has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL sol from CDSO.

The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday.

AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast cancer.

AstraZeneca and Daiichi Sankyo have reported results from the TROPION-Breast01 Phase III clinical trial of datopotamab deruxtecan (Dato-DXd) for breast cancer. The trial compared Dato-DXd to the investigator's choice of chemotherapy in patients with inoperable or metastatic hormone receptor (HR)-positive,